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Background: To describe changes in health-related quality of life (HRQoL) of postmenopausal women with
osteoporosis treated with teriparatide for up to 18 months and followed-up for a further 18 months, and to assess
the influence of recent prior and incident fractures.
Methods: The European Forsteo Observational Study (EFOS) is an observational, prospective, multinational study
measuring HRQoL using the EQ-5D. The primary objective was to assess changes in HRQoL during 36 months in
the whole study population. A secondary post-hoc analysis examined fracture impact on HRQoL in four subgroups
classified based on recent prior fracture 12 months before baseline and incident clinical fractures during the study.
Changes from baseline were analysed using a repeated measures model.
Results: Of the 1581 patients, 48.4% had a recent prior fracture and 15.6% of these patients had an incident
fracture during follow-up. 10.9% of the 816 patients with no recent prior fracture had an incident fracture. Baseline
mean EQ-VAS scores were similar across the subgroups. In the total study cohort (n = 1581), HRQoL (EQ-VAS and
EQ-5D index scores) improved significantly from baseline to 18 months and this improvement was maintained over
the 18-month post-teriparatide period. Improvements were seen across all five EQ-5D domains during teriparatide
treatment that were maintained after teriparatide was discontinued. Subjects with incident clinical fractures had
significantly less improvement in EQ-VAS than those without incident fractures. Recent prior fracture did not
influence the change in EQ-VAS during treatment.
Conclusions: EFOS is the first longitudinal study in women with severe postmenopausal osteoporosis in the real
world setting to show a substantial improvement in HRQoL during teriparatide treatment that was sustained during
subsequent treatment with other medications. The increase in HRQoL was lower in the subgroups with incident
fracture but was not influenced by recent prior fracture. The results should be interpreted in the context of the
design of an observational study.
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The quality of life of postmenopausal women with
osteoporosis is adversely affected if they have bone frac-
tures and pain [1-6]. Health-related quality of life
(HRQoL) has become an important outcome measure in
osteoporosis clinical trials and covers physical, emotional
and social functioning and well-being, which can be
assessed using generic or osteoporosis-specific question-
naires [1]. A decreased HRQoL is well documented in
postmenopausal women with osteoporosis-related frac-
tures, and this can vary according to type of fracture
[7-9], number and severity of fractures [4,10,11], and
time since fracture [12]. Some aspects of HRQoL are re-
duced in patients with subclinical vertebral fractures or
reduced bone mineral density [13], although low BMD is
generally regarded as asymptomatic. Additional factors,
such as comorbidities and back pain, may also influence
HRQoL, especially in older women [14,15].
Osteoporosis treatment aims to prevent fractures and,
in turn, to reduce morbidity and mortality. The efficacy
of osteoporosis medications in reducing the risk of fra-
gility fractures in postmenopausal women with osteopor-
osis has been demonstrated in randomised controlled
trials (RCTs), but there is only limited data that they are
capable of improving patient quality of life [16-20] or re-
duce mortality [21]. Teriparatide is a bone anabolic agent
that reduces the risk of vertebral and non-vertebral frac-
tures in postmenopausal women [22], but its effect on pa-
tient quality of life has not been thoroughly investigated.
Moreover, RCTs are conducted using carefully selected pa-
tients and there is limited data on HRQoL in routine clin-
ical practice, where patients with osteoporosis can have
multiple comorbidities, more severe disease, and receive
sequential treatment regimens. In addition, patient adhe-
rence or persistence with anti-osteoporosis therapies is
poor in everyday clinical practice [23,24] and may lead to
an increased fracture risk and reduced quality of life.
Therefore, data from observational studies can comple-
ment RCTs [25].
Results from the ICARO observational study showed
that osteoporotic women who sustained a new fragility
fracture during antiresorptive therapy had a lower
HRQoL score compared with patients without an inci-
dent fracture [26]. Similarly, in the Observational Study
of Severe Osteoporosis (OSSO), women with an inad-
equate response to osteoporosis therapy had a high rate
of incident fractures during 12 months’ treatment with
any osteoporosis medication, and this was associated
with worse HRQoL regardless of prior fracture status
[2]. An improvement in HRQoL during 18 months of
teriparatide treatment in the European Forsteo Obser-
vational Study (EFOS) has been reported [27]. However,
changes in HRQoL both during and after teriparatide
treatment in routine clinical practice have not beendescribed, nor has the influence of prior and incident
fractures on HRQoL during such treatment.
EFOS was a large 36-month, prospective, observational
study designed to evaluate fracture outcomes, back pain
and HRQoL in postmenopausal women with severe
osteoporosis treated with teriparatide in the outpatient
setting for a maximum of 18 months, followed by a
post-teriparatide treatment observational period of a fur-
ther 18 months. A reduced incidence of clinical vertebral
and non-vertebral fractures and reduction in back pain
over 36 months has been reported elsewhere [28].
The primary aim of this paper is to present a pre-
planned analysis of the HRQoL results in the EFOS study
population, both during teriparatide treatment for up to
18 months and in the subsequent 18-month period after
teriparatide discontinuation when patients were receiving
other osteoporosis medications. In addition, we perform a
secondary post-hoc analysis to examine the HRQoL
changes in patients grouped according to recent prior
fracture in the 12 months before the baseline assessment
and incident clinical fracture during 36 months follow-up.
Methods
Study design and patients
EFOS was a multicentre, prospective, observational study
of fracture outcomes, back pain and HRQoL in postmeno-
pausal women with osteoporosis in eight European coun-
tries (Austria, Denmark, France, Germany, Greece, Ireland,
the Netherlands, Sweden); the study design, sample size
considerations, and characteristics of the patient popula-
tion have been described in detail elsewhere [29]. Briefly,
1649 postmenopausal women with a diagnosis of osteopor-
osis who were about to initiate teriparatide treatment were
enrolled. Patients were followed for the duration of their
teriparatide treatment, which they could discontinue at any
time, and were asked to return for two additional visits
after they discontinued teriparatide. Patients were ex-
cluded from the study if they were currently being
treated with an investigational drug or procedure, or
had any contraindications as described in the teripa-
ratide label. The observational study design meant there
were no further restrictions for the selection of patients,
reflecting routine practice. All patients gave written in-
formed consent prior to enrolment and were able to
withdraw without consequence at any time. The study
was approved by local ethics committees or review
boards, depending on local requirements. The study
was conducted from April 2004 (first patient enrolled)
until February 2009 (last patient completed).
Data collection
At the baseline visit, patient demographic characteristics,
risk factors for osteoporosis and falls, osteoporosis ther-
apies and disease status were recorded [29]. The women
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18 months after teriparatide initiation, and at 6 and 18
months after discontinuing teriparatide treatment, dur-
ing which time the majority of patients took other osteo-
porosis medication, mainly bisphosphonates [27].
HRQoL was measured at each visit using the EQ-5D, a
generic self-administered health status questionnaire
that consists of two parts [30]. In the first part, patients
classify their own health status according to five dimen-
sions of health (mobility, self-care, usual activities, pain/
discomfort, and anxiety/depression) each of which is
scored on a three-point scale (no problems, some prob-
lems, or extreme problems). From the scores of these
five dimensions, a single index value is derived using a
general UK population-based algorithm, where an index
score of 0 represents a state equivalent to death and a
score of 1 represents a state of perfect health [31,32]. In
the second part of the EQ-5D, patients complete a visual
analogue scale (EQ-VAS), which assesses their perceived
overall health status on the day of scoring on a scale
from 0 (worst imaginable health state) to 100 (best im-
aginable health state).
At the baseline assessment, a patient’s history of fragility
fractures since the age of 40 years was collected by record-
ing the fracture location and date of each fracture. From
this information, a history of recent prior fracture within
the last 12 months before starting teriparatide was deter-
mined and categorised as yes or no. Information on inci-
dent clinical vertebral and non-vertebral fragility fractures
occurring during the study were collected at each follow-
up visit as self-reported by the patient; these fractures
were then diagnosed and confirmed by review of the ori-
ginal radiographs and/or the radiology or surgical reports
at the investigational site. A new or worsened vertebral
fracture was defined from the presence of a confirmed
radiographic vertebral fracture associated with signs and/
or symptoms suggestive of a vertebral fracture (such as
acute or severe back pain). Incident morphometric spine
fractures were not analysed in EFOS.
Statistical analysis
Data were analysed for the total study cohort, which in-
cluded all patients with a baseline visit and at least one
follow-up visit. The impact of fractures on patient
HRQoL was assessed in a post-hoc analysis by classifying
the total study population into four mutually exclusive
subgroups based on recent prior fracture in the 12
months before baseline (yes/no) and incident fracture
during the study (yes/no).
Descriptive statistics (e.g. frequencies and percentages
for categorical variables; means and standard deviations
(SD) or medians with 25th and 75th percentiles for con-
tinuous variables) were used to describe the total study
population and subgroups by recent prior and incidentfracture status. For EQ-VAS and EQ-5D index scores, a
last observation carried forward (LOCF) approach was
used for missing data.
Baseline characteristics between subgroups were com-
pared using Fisher exact tests for categorical variables,
Wilcoxon rank sum tests for time since most recent
fracture and number of previous fractures, and t-tests
for other continuous variables. The p-values of the pair-
wise comparisons were Bonferroni adjusted.
EQ-VAS changes from baseline were analysed using a
mixed model for repeated measures (MMRM) with an
unstructured correlation matrix and adjusting for age,
duration of prior bisphosphonate treatment and a diag-
nosis of rheumatoid arthritis at baseline. We adjusted
for age because it is associated with HRQoL [31]. Like-
wise, we adjusted for rheumatoid arthritis because it was
the most prevalent comorbidity in the patient cohort
and is associated with worse HRQoL regardless of frac-
ture status. Duration of prior bisphosphonate use was
included in the model as a surrogate of the severity of
osteoporosis and for consistency with the model used in
the primary analysis of the study (incident fractures).
Missing values are taken into account using this method.
The data are presented as adjusted mean changes from
baseline obtained after controlling for the covariates
(least-squares mean changes) with standard errors. P-
values for the within-group change from baseline repre-
sent the unique influence of the corresponding factor
after adjustment for the other factors in the model. Pair-
wise comparisons between subgroups (by fracture status)
in the adjusted least-squares mean change from baseline
at each follow-up visit were calculated, and the p-values
for the comparisons are presented.
For the EQ-5D index score, which was not normally dis-
tributed, Wilcoxon signed-rank test was used to assess
within-group changes from baseline. Between-group com-
parisons used Wilcoxon rank-sum tests and Bonferroni
adjusted p-values within each visit are reported.
All p-values presented are two-sided and the level of
significance is set to 5%. All data were analysed using
SAS software version 9.2.
Results
Patients
Of the 1649 postmenopausal women enrolled in the study,
1581 were analysed at baseline and returned for at least
one post-baseline visit (the total study cohort). Figure 1
presents the patient distribution for the secondary analysis
according to recent prior fracture status in the 12 months
before study entry and incident clinical fracture during the
study. Of the 1581 patients, 765 (48.4%) had a recent prior
fracture in the 12 months before study entry. Of these,
119 (15.6%) patients had an incident fracture during the
study. In the group of patients with no prior fracture in
Postmenopausal women enrolled
(n=1649)
No follow-up visit
(n=68) Total study cohort
(n=1581)
Recent prior fracture* 
(n=765)
No recent prior fracture*
(n=816)
Incident fracture
Group A
(n=119)
6 months
n=111
18 months
n=103
No incident fracture
Group B 
(n=646)
6 months
n=592
18 months
n=538
Incident fracture
Group C
(n=89)
6 months
n=86
18 months
n=84
No incident fracture
Group D
(n=727)
6 months
n=640
18 months
n=574
36 months
n=81
36 months
n=408
36 months
n=69
36 months
n=448
Te
rip
ar
at
id
e
tre
at
m
en
t f
or
 
u
p 
to
 1
8 
m
on
th
s
Figure 1 Study disposition. Patient distribution by recent prior fracture in the 12 months before study entry and by incident fracture during
the study.
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tients had an incident fracture during the study. Across
the subgroups, 79–94% of patients remained in the
study at 18 months and 62–78% were observed at the
36-month visit.
Table 1 summarises the baseline characteristics of the
total study cohort and the four subgroups by recent
prior and incident fracture status. There were few differ-
ences in baseline characteristics between the subgroups.
As expected (because of how the subgroups were de-
fined), the time since recent fracture and number of pre-
vious fractures after age 40 differed between groups.
However, for the time since most recent fracture, no dif-
ference was detected between patients with and without
incident fractures in the subgroups with recent prior
fracture in the 12 months before baseline (groups A and
B); the same was true for the subgroups without recent
prior fracture (groups C and D). Among the patients
with recent prior fracture, those with an incident frac-
ture (group A) had a significantly higher number of pre-
vious fractures than those without incident fracture
(group B, p < 0.05); no difference was seen between pa-
tients with and without incident fracture in the groups
with no recent prior fracture (groups C and D).
EQ-VAS
Table 2 presents the unadjusted EQ-VAS scores at each
visit for the total study population and for the four sub-
groups by recent prior and incident fracture status.
These unadjusted results are derived from the availabledata at the visits and support the adjusted analysis from
the MMRM (adjusted for age, duration of prior bis-
phosphonate treatment and a diagnosis of rheumatoid
arthritis) shown in Figure 2. For the total study cohort,
the unadjusted mean EQ-VAS score was 52.0 (SD 22.0)
at baseline, increasing to 67.5 (SD 21.4) at 18 months
and maintained at this level at 24 and 36 months
(Table 2). The within-group change from baseline was
significant at all visits (p < 0.001, Wilcoxon signed rank
test). Figure 2 shows an improvement in adjusted mean
EQ-VAS from baseline at all visits in the total study
cohort (p < 0.001 from MMRM); the increase from base-
line at 18 months was 11.3 (95%CI 9.7–12.8) and this
was maintained during the post-teriparatide treatment
period: 10.0 (95%CI 8.3–11.7) at 24 months and 10.7
(95%CI 8.9–12.5) at 36 months.
In the secondary post-hoc analysis, the four subgroups
of patients according to recent prior and incident frac-
ture status did not differ in their baseline mean EQ-VAS
scores (Table 2). Figure 2 shows significant within-group
changes from baseline in the adjusted mean EQ-VAS for
all subgroups (p < 0.05 from MMRM), except for the no
recent prior/incident fracture subgroup at 6, 24 and 36
months. Figure 2 also shows that the two subgroups
with incident fracture (dotted lines) had significantly less
improvement in adjusted mean EQ-VAS (irrespective of
recent prior fracture) than the two subgroups without
incident fracture (solid lines, p < 0.05 for all comparisons
at 18 and 36 months). Notably, the no recent prior frac-
ture plus no incident fracture subgroup showed a clear
Table 1 Baseline characteristics of the four subgroups and total study cohort
Total study
cohort
(n = 1581)
Group A Group B Group C Group D
Recent prior fracturea;
incident fracture
(n = 119)
Recent prior fracturea;
no incident fracture
(n = 646)
No recent prior fracturea;
incident fracture
(n = 89)
No recent prior fracturea;
no incident fracture
(n = 727)
Age (years) 71.0 (8.4) 72.1 (8.6) 71.3 (8.1) 70.6 (9.0) 70.5 (8.5)
Caucasian, % 99.2 100 99.1 100 99.1
Body Mass Index (kg/m2) 25.1 (4.3) 25.1 (4.6) 25.3 (4.2) 24.3 (4.0) 25.1 (4.3)
Early menopause (<40
years of age), %
8.9 7.9 7.9 11.9 9.6
Surgical menopause, % 18.1 20.2 15.9 23.6 19.0
Nulliparous, % 13.0 11.8 12.8 11.5 13.6
Current smoker, % 13.0 10.9 10.9 19.5 14.5
Osteoporotic hip fracture
in mother, %
20.8 22.3 22.2 18.2 19.7
Time since most recent
fracture (years)
2.0 (3.4) 0.3 (0.3) 0.3 (0.3) 4.5 (3.9)** 4.2 (4.1)**
Number of previous
fractures after 40 years of
age
2.9 (2.0) 4.0 (2.0)# 3.3 (1.9) 3.3 (2.3) 2.3 (1.9)††
Lumbar spine BMD T-
score
−3.26 (1.16) −3.26 (1.16) −3.18 (1.22) −3.45 (1.02) −3.31 (1.13)
Total hip BMD T-score −2.61 (1.05) −2.82 (0.87) −2.53 (1.11) −2.79 (1.12) −2.61 (1.00)
Back pain VAS 57.8 (26.6) 60.1 (26.5) 58.8 (26.2) 60.0 (25.2) 56.1 (27.1)
Uses arms when stands
up from chair, %
63.3 70.6 65.0 47.7*‡ 62.6
Sight problems, % 45.0 54.6 43.2 52.3 44.1
>1 fall in last year, % 42.0 53.8 45.0 42.0 37.4*
Prior osteoporosis
medication, %
91.8 96.6 89.6 98.9‡ 92.2
Prior bisphosphonate
medication, %
73.4 76.5 70.7 87.6‡# 73.6
Comorbidities, %
Rheumatoid arthritis 11.9 15.1 13.9‡ 16.9 8.9
Chronic obstructive
pulmonary disease
8.7 13.4 9.0 5.6 8.1
Diabetes mellitus 5.5 6.7 5.1 4.5 5.8
Concomitant medications,
%
Antihypertensives 37.2 37.8 38.8 31.4 36.4
Glucocorticoids 14.8 20.2 15.4 19.8 12.8
Thyroid hormones 13.3 10.9 15.1 18.6 11.6
Benzodiazepines 12.0 16.0 11.5 16.3 11.3
Antidepressants 10.2 17.6‡ 10.6 12.8 8.4
Data are presented as mean (SD) unless indicated otherwise.
aRecent prior fracture within the last 12 months before baseline visit.
Comparisons between groups used Fisher exact tests for categorical variables, Wilcoxon signed-rank tests for time since most recent fracture and number of
previous fractures, and t-tests for other continuous variables (all Bonferroni adjusted p-values).
*p < 0.05, **p < 0.001 for pairwise comparisons with groups A and B.
††p < 0.001 for pairwise comparisons with groups A, B, and C.
‡ p < 0.05 for pairwise comparison with group D.
# p < 0.05 for pairwise comparison with group B.
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Table 2 Unadjusted EQ-VAS and EQ-5D index scores at each study visit
Visit Total study
population
(N = 1561)
Group A Group B Group C Group D
Recent prior fracturea;
incident fracture
(N = 119)
Recent prior fracturea;
no incident fracture
(N = 646)
No recent prior fracturea;
incident fracture
(N = 89)
No recent prior fracturea;
no incident fracture
(N = 727)
n n n n n
EQ-VAS, mean (SD)
Baseline 1558 52.01(22.0) 117 48.4 (22.0) 636 51.4 (21.8) 88 49.3 (21.6) 717 53.5 (22.1)
3 months 1434 59.0 (19.8) 105 54.9 (18.9) 584 59.3 (19.6) 81 55.2 (17.4) 664 59.8 (20.4)
6 months 1401 61.94(20.1) 110 56.1 (17.8)*† 579 63.3 (19.0) 85 53.6 (19.8)‡ 627 62.9 (21.0)
12 months 1304 64.5 (21.4) 106 56.5 (20.7)**†† 528 65.5 (20.5) 84 57.9 (17.9)‡ 586 66.0 (22.4)
18 months 1249 67.5 (21.4) 101 60.6 (20.9)**†† 514 68.8 (20.5) 79 57.8 (18.8)‡‡ 555 68.9 (22.1)
24 months 1068 67.4 (22.4) 91 58.9 (24.1)**† 416 69.6 (20.9) 71 54.8 (21.0)‡‡ 490 68.9 (22.6)
36 months 951 68.7 (22.5) 79 60.1 (23.7)*† 385 70.2 (21.6) 65 57.9 (22.4)‡‡ 422 70.7 (22.3)
Endpointb 1513 64.6 (23.1) 116 57.1 (24.3)*† 615 65.5 (22.5) 84 55.7 (22.5)‡‡ 698 66.2 (23.2)
EQ-5D index score, median (Q1, Q3)
Baseline 1535 0.59 (0.08,0.73) 116 0.23 (−0.02, 0.67)†† 623 0.59 (0.03, 0.73) 86 0.57 (0.17, 0.69) 710 0.59 (0.09, 0.73)
3 months 1409 0.69 (0.52, 0.76) 103 0.62 (0.29, 0.73)*† 577 0.69 (0.52, 0.76) 80 0.62 (0.23, 0.74) 649 0.69 (0.52, 0.80)
6 months 1367 0.69 (0.52, 0.80) 108 0.62 (0.52, 0.71)**†† 564 0.69 (0.59, 0.80) 83 0.62 (0.26, 0.73)‡‡ 612 0.69 (0.59, 0.80)
12 months 1289 0.69 (0.59, 0.80) 106 0.69 (0.52, 0.76)*†† 522 0.69 (0.59, 0.80) 85 0.62 (0.26, 0.73)‡‡ 576 0.73 (0.59, 0.85)
18 months 1233 0.73 (0.59, 0.85) 102 0.66 (0.52, 0.74)**†† 513 0.73 (0.62, 0.85) 80 0.62 (0.52, 0.76)‡‡ 538 0.73 (0.59, 0.85)
24 months 1057 0.73 (0.59, 0.85) 87 0.62 (0.09, 0.73)**†† 410 0.73 (0.62, 0.88) 73 0.69 (0.31, 0.80)‡ 487 0.73 (0.59, 0.88)
36 months 939 0.73 (0.59, 0.88) 75 0.62 (0.15, 0.76)**†† 377 0.76 (0.62, 1.00) 66 0.69 (0.52, 0.80)‡ 421 0.76 (0.62, 1.00)
Endpointb 1483 0.69 (0.52, 0.80) 111 0.59 (0.09, 0.76)**†† 605 0.69 (0.59, 0.80) 85 0.69 (0.36, 0.76)‡ 682 0.73 (0.52, 0.85)
For the EQ-VAS and EQ-5D index scores, a higher score represents a better quality of life.
Teriparatide treatment was initiated at baseline and continued for up to 18 months; other osteoporosis medications were used between 18 and 36 months after
teriparatide was discontinued.
aRecent prior fracture within the last 12 months before baseline visit.
bMissing data was handled using the last observation carried forward (LOCF) method.
Between-group comparisons (Wilcoxon rank-sum test; Bonferroni adjusted p-values).
*p < 0.05, ** p < 0.001 for pairwise comparison of group A versus group B.
†p < 0.05, ††p < 0.001 for pairwise comparison of group A versus group D.
‡p < 0.05, ‡‡p < 0.001 for pairwise comparison of group C versus groups B and D.
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was maintained at 36 months (as did the recent fracture
plus no incident fracture subgroup). Pairwise compari-
sons revealed no significant differences at any visit in the
change in EQ-VAS between the two subgroups with in-
cident fractures (Groups A and C) or between the two
subgroups with no incident fracture (Groups B and D)
(Figure 2), indicating that recent prior fracture does not
influence the change in HRQoL.
EQ-5D index scores
Median (Q1, Q3) EQ-5D index scores for the total study
cohort increased from 0.59 (0.08, 0.73) at baseline to 0.73
(0.59, 0.85) at 18 months and were maintained at this me-
dian value after teriparatide discontinuation (Table 2). The
median (Q1, Q3) change from baseline in EQ-5D index
scores for the total study cohort (Table 3) was significant at
each follow-up visit (p < 0.001, Wilcoxon signed rank test
for within-group change).In the secondary post-hoc analysis, the baseline median
EQ-5D index scores differed significantly between the sub-
group with recent prior and incident fractures (group A)
and the subgroup without recent prior and incident frac-
tures (group D) (0.23 [Q1, Q3: -0.02, 0.67] vs. 0.59 [Q1,
Q3: 0.09, 0.73]; p < 0.001); all other pairwise comparisons
at baseline were non-significant (Table 2). The median
(Q1, Q3) changes from baseline in EQ-5D index scores
for the four subgroups by recent prior and incident frac-
ture status (Table 3) shows large variability at each visit,
but there was a trend for improvement to 18 months that
was maintained to 36 months (p < 0.05 for within-group
change from baseline for each subgroup, Wilcoxon signed
rank test). Pairwise comparisons in the change from base-
line at the 18 and 36 month visits showed there was signifi-
cantly less improvement in EQ-5D index score in the
subgroup with no recent prior/incident fracture (group C)
compared with the recent prior/no incident fracture sub-
group (group B) (Bonferroni adjusted p values; p < 0.05 at
Recent prior fracture + incident fracture (Group A)
Recent prior fracture + no incident fracture (Group B)
No recent prior fracture + incident fracture (Group C)
No recent prior fracture + no incident fracture (Group D)
Total study population
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Figure 2 EQ-VAS changes from baseline. Adjusted mean (SE) change in EQ-VAS from baseline during and after teriparatide treatment in the
total study cohort and according to recent prior fracture (within last 12 months) and incident fracture status. Data presented is from the MMRM
analysis (adjusted for age, duration of prior bisphosphonate treatment and a diagnosis of rheumatoid arthritis at baseline). All p < 0.05 for within-
group change from baseline (except for no recent prior/incident fracture at 6, 24 and 36 months). Significant pairwise comparisons between
subgroups at 18 and 36 months are shown in the figure but the same pairwise comparisons were significant (p < 0.05) at 6, 12 and 24 months.
*p < 0.05 for recent prior/incident fracture (group A) versus recent prior/no incident fracture (group B); †p < 0.05 for recent prior/incident fracture
(group A) versus no recent prior/no incident fracture (group D); ‡ p < 0.001 for recent prior/no incident fracture (group B) versus no recent prior/
incident fracture (group C); X p < 0.001 for no recent prior/incident fracture (group C) versus no recent prior/no incident fracture (group D). Note:
variability (standard error bars) only added to the graph at two time points (18 and 36 months) for clarity.
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two time points were non-significant (Table 3).
EQ-5D domains
For the total study cohort, there were improvements from
baseline in all five EQ-5D domains during teriparatideTable 3 Median change from baseline in EQ-5D index score
Visit Total study
cohort (n = 1581)
Group A Gro
Recent prior fracturea;
incident fracture
(n = 119)
Recent prio
no inciden
(n =
3 months 0.07 (0.00, 0.37) 0.07 (0.00, 0.50) 0.10 (0.0
6 months 0.11 (0.00, 0.46) 0.10 (0.00, 0.53) 0.14 (0.0
12 months 0.12 (0.00, 0.46) 0.17 (0.00, 0.60) * 0.14 (0.0
18 months 0.15 (0.00, 0.50) 0.17 (−0.03, 0.57) 0.20 (0.0
24 months 0.17 (0.00, 0.47) 0.10 (−0.04, 0.50) § 0.21 (0.00
36 months 0.17 (0.00, 0.48) 0.15 (−0.07, 0.60) 0.20 (0.0
aRecent prior fracture within the last 12 months before baseline visit.
Data given in brackets are the interquartile range (Q1, Q3).
All p < 0.05 for within-group change from baseline (Wilcoxon signed rank test).
Between group comparisons at each visit (Wilcoxon rank-sum tests, Bonferroni adju
* p < 0.05 for pairwise comparison of group A versus group C.
† p < 0.05 for pairwise comparison of group B versus group C.
‡ p < 0.05 for pairwise comparison of group B versus group D.
# p < 0.05 for pairwise comparison of group C versus group D.
§ p < 0.05 for pairwise comparison of group A versus group B.treatment that were maintained after teriparatide was
discontinued. The percentage of women reporting extreme
problems in the five domains was reduced at all post-
baseline visits and Figure 3 shows the results at 18 and 36
months. The highest frequency of extreme problems was
in the usual activities and pain/discomfort domains.up B Group C Group D
r fracturea;
t fracture
646)
No recent prior fracturea;
incident fracture
(n = 89)
No recent prior fracturea;
no incident fracture
(n = 727)
0, 0.51) ‡ 0.04 (0.00, 0.27) 0.04 (0.00, 0.27)
0, 0.53) † 0.04 (0.00, 0.26) 0.11 (0.00, 0.41)
0, 0.53) † 0.04 (−0.05, 0.27) # 0.11 (0.00, 0.43)
0, 0.53) † 0.04 (−0.04, 0.40) 0.13 (0.00, 0.43)
, 0.57) †, ‡ 0.11 (−0.07, 0.33) 0.11 (0.00, 0.38)
0, 0.57) † 0.09 (0.00, 0.33) 0.16 (0.00, 0.38)
sted p-values).
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(d) Group C - no recent prior fracture plus incident fracture 
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(e) Group D - no recent prior fracture plus no incident fracture  
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Figure 3 Extreme problems in EQ-5D domains. Patients (%) reporting extreme problems at baseline and at 18- and 36-months follow-up in
the five domains of EQ-5D for (a) the total study cohort, (b) group A with recent prior fracture and incident fracture; (c) group B with recent
prior fracture and no incident fracture; (d) group C with no recent prior fracture and incident fracture; and (e) group D with no recent prior
fracture and no incident fracture. The remaining patients in each group reported either no problems or some problems for each domain.
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http://www.biomedcentral.com/1471-2474/14/251Figure 3 also shows the percentage of women reporting
extreme problems in the five EQ-5D domains at baseline
and 18 and 36 months follow-up for the four subgroups
according to recent prior and incident fracture status. As
expected, for all five domains the frequency of extreme
problems was higher at baseline for the two subgroups
with recent prior fracture (groups A and B) than the two
groups with no recent prior fracture (groups C and D).
Also, the frequency of extreme problems was higher at 18-
and 36-months follow-up in the subgroups with incident
fractures (groups A and C) than in the subgroups with no
incident fractures (groups B and D). Thus, the proportion
with extreme problems was highest at baseline and during
follow-up in the subgroup of women with both recent
prior and incident fractures (group A). The proportion of
patients reporting extreme problems in the two subgroups
with no incident fractures (groups B and D) decreased
during follow-up.
Discussion
EFOS is the first study to longitudinally examine health-
related quality of life in postmenopausal women with se-
vere osteoporosis in routine clinical practice both during
and after teriparatide treatment. The results show that
HRQoL (measured using the EQ-5D) is substantially im-
proved during teriparatide treatment for up to 18 months
and, importantly, is maintained during the 18-month
post-teriparatide period while patients are receiving other
osteoporosis treatments (mainly bisphosphonates, asdescribed previously by Fahrleitner-Pammer et al. [27]).
Notably, improvements were seen across all five EQ-5D
domains during teriparatide treatment. The HRQoL re-
sults are consistent with the back pain results already
reported for this study cohort [27]. Our analysis also
shows that when the quality of life data are broken down
according to recent prior and incident clinical fracture sta-
tus, all four subgroups have a comparable but low EQ-
VAS at baseline and show a trend for improvement during
the study. However, the increase in EQ-VAS is smaller in
patients who had an incident fracture at some point dur-
ing the study compared with those without an incident
fracture. Recent prior fracture in the 12 months before the
study does not appear to influence the change in EQ-VAS
during the study.
Interestingly, the results for the subgroup with no recent
prior fracture plus no incident clinical fracture showed a
low level of HRQoL at baseline and an increase during
treatment. Our finding of a low baseline HRQoL even in
the subgroup with no recent prior fracture is consistent
with a recent systematic review, which reported that
HRQoL is adversely affected by osteoporosis in the ab-
sence of vertebral fracture [33]. However, it may also be a
consequence of our patient stratification. We have previ-
ously reported that, at baseline, 91.9% of the women in the
EFOS study had a previous fracture since the age of 40
years and 70% had two or more vertebral deformities [28].
As those with prior fractures older than 12 months at
baseline were included in the no recent prior fracture
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cident fracture subgroup may be due to teriparatide effects
on these older fractures. Teriparatide effects on other fac-
tors may also be involved in driving the quality of life im-
provement. These include relief of back pain, which is a
major contributor to disability and has a negative impact
on HRQoL [15]. Also, only clinical fractures were consid-
ered in EFOS and, as it has been shown that only about
30% of vertebral fractures are clinically diagnosed [34], pa-
tients may have undiagnosed fractures that are impacting
on their quality of life [1]. It is possible that improvements
in microfractures are contributing to the improved
HRQoL and the beneficial effects of teriparatide on back
pain may be related to the prevention and healing of
microfractures [35,36], but this remains to be proven. The
reduced risk of back pain in teriparatide-treated patients
has been associated with a reduction in the severity and
number of new vertebral fractures [37]. However, the anti-
pain effect of teriparatide cannot be fully explained by ver-
tebral fracture reduction or accelerated fracture healing,
although there are very few publications suggesting what
the possible reasons could be. A potential CNS effect of
teriparatide cannot be excluded, but has not been shown
so far [36]. Another possible explanation for the improve-
ment in HRQoL is that it is a placebo effect resulting from
the regular contact with study investigators. Further work
is needed to identify other possible factors associated with
the observed improvement in HRQoL during and after
teriparatide treatment.
Our results are consistent with a substudy from the
placebo-controlled Fracture Prevention Trial (FPT) of
teriparatide treatment in postmenopausal women with
severe osteoporosis, which examined the associations
between fractures and HRQoL measured using the Osteo-
porosis Assessment Questionnaire [10,38]. All women in
the FPT had a prevalent vertebral fracture at baseline and
were at risk of subsequent fractures. Those with more se-
vere vertebral fractures at baseline had a lower baseline
HRQoL [10]. Women with incident fractures (vertebral
and non-vertebral) had a worse HRQoL (physical function,
symptoms and emotional status dimensions) during the
study than women without incident fractures, regardless of
treatment group [38]. Another large RCT evaluating deno-
sumab treatment also demonstrated that incident clinical
fractures have an adverse impact on HRQoL in postmeno-
pausal women with osteoporosis [39].
We measured HRQoL using the generic EQ-5D ques-
tionnaire rather than an osteoporosis-specific question-
naire. EQ-5D is a validated standardised instrument for
the measurement of health status. A generic instrument
has advantages because it enables comparison of health
effects between diseases and is the instrument of choice
in health technology assessment. Previous studies using
EQ-5D have shown an impaired quality of life statusafter fracture together with gradual improvements over
the subsequent year [40]. Thus, EQ-5D is sensitive to
change in patients with osteoporosis-related fractures.
Although there have been no reports of what constitutes
a clinically-relevant change in EQ-VAS scores for pa-
tients with osteoporosis, studies in other diseases indi-
cate that EQ-VAS is responsive to changes in health and
that a mean change in the score of 10.9 to 12.1 is a
meaningful difference for improved health [41,42]. A
change of 0.03 in the EQ-5D index score is considered a
minimum clinically important difference in patients with
osteoporosis [43].
At baseline, the unadjusted mean EQ-VAS score of 52.0
for the total study cohort indicated that patients had worse
quality of life compared with the German population
norm for women aged 70–79 years old (mean 75.5) [31].
We compared our results with population norms for
Germany because this country provided 25% of the pa-
tients taking part in EFOS [29]. The mean EQ-VAS values
at 18 and 36 months (67.5 and 68.7, respectively) showed
improvement in HRQoL. Although HRQoL decreases
with age in the general population [31], the EQ-VAS
scores of patients participating in the present study in-
creased over time; however, EQ-VAS was still lower than
in an age-matched general German female population. In
agreement with Dhillon et al. [14], we found the most
problematic EQ-5D domains were pain/discomfort and
usual activities; these two domains were also the most im-
proved during teriparatide treatment.
Our results of an improvement in HRQoL during
teriparatide treatment are consistent with a small retro-
spective single centre study of 57 patients with osteopor-
osis, which showed that HRQoL (assessed using the
mini-Osteoporosis Quality of Life Questionnaire) im-
proved with teriparatide treatment in a clinical practice
setting [44]. Also, the PROPOSE observational study has
shown HRQoL improvements during treatment with
rhPTH(1–84) [45]. Although several randomised clinical
trials have shown that other osteoporosis treatments
(alendronate, strontium ranelate and zoledronic acid) have
some beneficial effects on HRQoL in postmenopausal
women [16-20], it is difficult to make comparisons be-
tween studies because of differences in study design, pa-
tient populations and methods used. Nevertheless, despite
receiving previous osteoporosis treatment(s) and having
multiple comorbidities, the patients in EFOS experienced
substantial improvements in HRQoL during teriparatide
treatment. As they received other osteoporosis medica-
tions after discontinuing teriparatide, those medications
may have contributed to the maintenance of HRQoL en-
hancement associated with teriparatide treatment.
One of the most interesting findings of the study is the
influence of recent prior and incident fracture on
HRQoL. We observed that women with an incident
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study than patients with no incident fracture. However,
recent prior fracture in the 12 months before baseline
did not seem to influence the change in HRQoL either
during or after teriparatide treatment. These findings are
consistent with the OSSO study, which assessed the im-
pact of fracture on HRQoL (EQ-5D and QUALEFFO) at
baseline and at 6 and 12 months of treatment with any
osteoporosis medication [2]. As in our study, HRQoL
was worse in patients with an incident fracture regard-
less of recent prior fracture status [2]. Recent prior frac-
ture in the months before baseline was associated with
an increased risk of incident fracture and worse HRQoL
at baseline compared with no recent prior fracture [2].
In contrast, however, Dhillon et al. [14] found no signifi-
cant difference in EQ-5D scores between patients with
and without a history of prior fracture.
Although incident fracture is associated with worse
HRQoL, we cannot assume a causal relationship. In our
analysis of EQ-VAS we adjusted for patient age, duration
of prior bisphosphonate treatment and a diagnosis of
rheumatoid arthritis, but many other factors may influ-
ence HRQoL, including other comorbidities, back pain,
and lifestyle [46].
Our study has several limitations. First, this is a non-
comparative study without a control group, and the sub-
groups of patients with incident fractures were small.
The difference in sample size between the subgroups
may limit the results. Second, incident fractures were
those that were clinically recognised and patients could
have had morphometric spine fractures not detected
clinically. Third, EQ-5D assesses health status on the
day of measurement and there were significant time gaps
between HRQoL measurements. Fourth, the EQ-5D re-
sults may be influenced by patient drop-outs during the
study. For EQ-VAS, this problem was reduced by apply-
ing the MMRM. For the other EQ-5D variables (EQ-5D
index scores and domain scores), the LOCF method may
have overestimated the improvement over time. Finally,
comorbidities can impact on patient quality of life; al-
though the baseline data suggests that the subgroups
were reasonably well balanced regarding comorbidities.
The strengths of our study include the large sample
size with few eligibility restrictions, allowing recruitment
of a diverse range of subjects, many of whom had co-
morbidities and were taking concomitant medications.
Other strengths include the prospective assessment of
HRQoL both during and after teriparatide discontinuation
in the normal clinical practice setting, and adjustment in
the analysis for factors that may influence HRQoL, such
as age, duration of prior bisphosphonate treatment and a
diagnosis of rheumatoid arthritis. It also shows a clinically
meaningful improvement in a relevant, patient-related
outcome that is consistent across all patient groups.Conclusions
In this large pragmatic study of postmenopausal women
with severe osteoporosis, we have observed a clinically
meaningful improvement in HRQoL during teriparatide
treatment that is maintained after teriparatide is dis-
continued when most patients are receiving other
osteoporosis medications. We have demonstrated that
the improvement in HRQoL is unaffected by a previous
history of a recent fracture in the last 12 months before
starting treatment but, as expected, was attenuated by
incident clinical fractures. Further studies will be
needed to understand the underlying mechanisms; how-
ever, this study for the first time demonstrated that a
clinically-relevant improvement in HRQoL was main-
tained after stopping teriparatide treatment in addition
to previously demonstrated positive effects on clinical
fracture. However, because of the open label and non-
comparative nature of the present study, our findings
need confirmation through a randomised, controlled,
double-blind study.
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